CHI Announces Technological Challenges with Antibody Drug Conjugates at Cancer Biologics 2012

Jan. 26, 2012 - PRLog -- NEEDHAM, MASS. – Cambridge Healthtech Institute announces Technological Challenges with Antibody Drug Conjugates.  This roundtable discussion will be held during  during the Cancer Biologics Conference at the Tri-Conference.

Featuring over 25 presentations, this unique three-day conference presents advances in antibody drug conjugates, multi-specifics, drug combinations, enhanced targeting and PKPD, translational studies and immunotherapy, is being held at the Molecular Med TRI-CON 2012 on Feb. 21-23 at the Moscone in San Francisco.

Moderated by:  Ho Sung Cho, Ph.D., Chief Technical Officer, Ambrx. Join leading cancer research experts to discuss:

* Determining the best combination of warhead and target
   * Selection of right linker technology for the product
   * Ensuring uptake, internalization and activation of the product
   * Ensuring specificity to tumor cells and not normal ones
   * In vitro studies and in animal models
         o Selection of good predictive biomarkers
         o Challenges with optimizing performance
         o Challenges with toxicity
   * Challenges with characterization (heterogeneous) and comparability


For more information and to view the full agenda visit, http://www.triconference.com/Cancer-Biologics/

The Cancer Biologics conference is one of the program offerings at CHI’s flagship event, the Molecular Medicine Tri-Conference (February 19-23).  This international event features 2 partnering forums, 5 symposia, 18 short courses, and 12 core programs around 4 scientific channels: diagnostics, drug discovery & development, informatics, and cancer. Over 3000 attendees and 150+ sponsors & exhibitors will gather in shared networking functions and in the exhibit/poster hall.

To view the entire conference agenda and to register, please visit http://www.triconference.com/Cancer-Biologics/

Writers and editors are encouraged to attend. To request a press pass, contact Tracey Fielding at tfielding@healthtech.com.

About Cambridge Healthtech Institute (www.chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

# # #

Since 1992, Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations.